SNS-723

N/A

Report date: 2024/10/22 14:50:50

Base Information

Drug NameSNS-723

Drug Alias NameASPH targeted CAR-T cell therapy - Sensei BiotherapeuticsSNS-723

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAspartyl (asparaginyl) β-hydroxylase modulators

TargetsAspartyl (asparaginyl) β-hydroxylase

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPanacea Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesSensei Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A